Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections
RK Shields, DL Paterson… - Clinical Infectious …, 2023 - academic.oup.com
Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is one of
the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant …
the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant …
[HTML][HTML] Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside
MF Lin, CY Lan - World Journal of Clinical Cases: WJCC, 2014 - ncbi.nlm.nih.gov
Acinetobacter baumannii (A. baumannii) is undoubtedly one of the most successful
pathogens in the modern healthcare system. With invasive procedures, antibiotic use and …
pathogens in the modern healthcare system. With invasive procedures, antibiotic use and …
Rationalizing antimicrobial therapy in the ICU: a narrative review
The massive consumption of antibiotics in the ICU is responsible for substantial ecological
side effects that promote the dissemination of multidrug-resistant bacteria (MDRB) in this …
side effects that promote the dissemination of multidrug-resistant bacteria (MDRB) in this …
Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America …
It is important to realize that guidelines cannot always account for individual variation among
patients. They are not intended to supplant physician judgment with respect to particular …
patients. They are not intended to supplant physician judgment with respect to particular …
Carbapenem-resistant Acinetobacter baumannii: Colonization, Infection and Current Treatment Options
C Bartal, KVI Rolston, L Nesher - Infectious diseases and therapy, 2022 - Springer
Carbapenem-resistant Acinetobacter baumannii (CRAB) causes colonization and infection
predominantly in hospitalized patients. Distinction between the two is a challenge. When …
predominantly in hospitalized patients. Distinction between the two is a challenge. When …
[HTML][HTML] European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram …
Scope These ESCMID guidelines address the targeted antibiotic treatment of third-
generation cephalosporin-resistant Enterobacterales (3GCephRE) and carbapenem …
generation cephalosporin-resistant Enterobacterales (3GCephRE) and carbapenem …
New perspectives on antimicrobial agents: cefiderocol
Bacterial resistance to carbapenem agents has reached alarming levels. Accordingly,
collaborative efforts between national and international organizations and the …
collaborative efforts between national and international organizations and the …
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
In the face of diminishing therapeutic options for the treatment of infections caused by
multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and …
multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and …
Acinetobacter baumannii: evolution of antimicrobial resistance—treatment options
The first decade of the 20th century witnessed a surge in the incidence of infections due to
several highly antimicrobial-resistant bacteria in hospitals worldwide. Acinetobacter …
several highly antimicrobial-resistant bacteria in hospitals worldwide. Acinetobacter …
[HTML][HTML] Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment
Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) has gained
global notoriety as a critically important nosocomial pathogen. It mostly affects debilitated …
global notoriety as a critically important nosocomial pathogen. It mostly affects debilitated …